CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Cancer Research

• Publication date

  2005-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0028-3770(05)83427-7PMID 15297393
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Temozolomide in the treatment of recurrent malignant glioma

  2004cited by this paper
• Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide

  2004cited by this paper
• Correlation between Promoter Hypermethylation of the O6-Methylguanine-Deoxyribonucleic Acid Methyltransferase Gene and Prognosis in Patients with High-grade Astrocytic Tumors Treated with Surgery, Radiotherapy, and 1-(4-Amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based Chemot

  2004cited by this paper
• Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer

  2004cited by this paper
• Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway.

  2003cited by this paper
• Promoter Hypermethylation of the DNA Repair Gene O6‐Methylguanine‐DNA Methyltransferase is an Independent Predictor of Shortened Progression Free Survival in Patients with Low‐grade Diffuse Astrocytomas

  2003cited by this paper
• Cancer pharmacogenetics: polymorphisms, pathways and beyond

  2003cited by this paper
• Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase π in glioblastoma and the survival of the patients treated with nimustine hydrochloride: An immunohistochemical analysis

  2003cited by this paper
• Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

  2003cited by this paper
• Relevance of DNA methylation in the management of cancer.

  2003cited by this paper
• Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.

  2003cited by this paper
• Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.

  2003cited by this paper
• Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

  2003cited by this paper
• Gene silencing in cancer in association with promoter hypermethylation.

  2003cited by this paper
• The Effect of O 6-Alkylguanine-DNA Alkyltransferase and Mismatch Repair Activities on the Sensitivity of Human Melanoma Cells to Temozolomide, 1,3-bis(2-Chloroethyl)1-nitrosourea, and Cisplatin

  2003cited by this paper
• Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome.

  2003cited by this paper
• O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.

  2003cited by this paper
• Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma.

  2002cited by this paper
• The treatment of brain metastases from malignant melanoma.

  2002cited by this paper
• Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients.

  2002cited by this paper
• Clinical relevance of MGMT in the treatment of cancer.

  2002cited by this paper
• Inactivation of O6‐Methylguanine‐DNA Methyltransferase in Human Lung Adenocarcinoma Relates to High‐grade Histology and Worse Prognosis among Smokers

  2002cited by this paper
• Deficient expression ofO6-Methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma

  2002cited by this paper
• Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.

  2001cited by this paper
• Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene.

  2001cited by this paper
• Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.

  2001cited by this paper
• Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.

  2001cited by this paper
• Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.

  2000cited by this paper
• Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.

  2000cited by this paper
• Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

  2000cited by this paper
• Pharmacogenomics--teaching old drugs new tricks.

  2000cited by this paper
• Repair of O(6)-alkylguanine by alkyltransferases.

  2000cited by this paper
• Repair of O6-alkylguanine by alkyltransferases

  2000cited by this paper
• Role of O6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity.

  1999cited by this paper
• Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.

  1999cited by this paper
• A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers

  1999cited by this paper
• O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy.

  1999cited by this paper
• Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

  1999cited by this paper
• Cancer-epigenetics comes of age

  1999cited by this paper
• O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics.

  1998cited by this paper
• Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.

  1998cited by this paper
• O6‐methylguanine‐DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts

  1998cited by this paper
• Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene

  1997cited by this paper
• O6-benzylguanine and its role in chemotherapy.

  1997influential reference
• Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene.

  1997cited by this paper
• Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine.

  1996cited by this paper
• Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

  1996cited by this paper
• DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal.

  1990cited by this paper
• Cancer: Principles and Practice of Oncology

  1983cited by this paper
• Deficient Expression of O 6-Methylguanine-DNA Methyltransferase Combined With Mismatch-Repair Proteins hMLH 1 and hMSH 2 Is Related to Poor Prognosis in Human Biliary Tract Carcinoma

  year unknowncited by this paper

• Cancer‐Type‐Specific DNA Methylation Is a Source of Vulnerability in Liver Cancer Cells

  2025cites this paper
• Magnetic resonance imaging fractal analysis of O(6)-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase wild-type glioblastoma

  2025cites this paper
• Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT.

  2024cites this paper
• Distinct Capabilities in NAD Metabolism Mediate Resistance to NAMPT Inhibition in Glioblastoma

  2024cites this paper
• Importance of Autophagy Regulation in Glioblastoma with Temozolomide Resistance

  2024cites this paper
• Revisiting Temozolomide's role in solid tumors: Old is gold?

  2024cites this paper
• Prediction of O(6)-methylguanine-DNA methyltransferase promoter methylation status in IDH-wildtype glioblastoma using MRI histogram analysis

  2024cites this paper
• A qPCR technology for direct quantification of methylation in untreated DNA

  2023cites this paper
• From Theory to Practice: Implementing the WHO 2021 Classification of Adult Diffuse Gliomas in Neuropathology Diagnosis

  2023cites this paper
• Epigenetics in cancer development, diagnosis and therapy.

  2023cites this paper
• Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors

  2023cites this paper
• MGMT and Whole-Genome DNA Methylation Impacts on Diagnosis, Prognosis and Therapy of Glioblastoma Multiforme

  2022influential citation
• A bibliometric and visualization-based analysis of temozolomide research hotspots and frontier evolution

  2022cites this paper
• S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial

  2022cites this paper
• DNA Methylation Profiling: An Emerging Paradigm for Cancer Diagnosis.

  2021cites this paper
• Immunohistochemical expression of MGMT in gliomas and its role in ascertaining patient survival

  2021cites this paper
• Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias

  2021cites this paper
• The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead

  2020cites this paper
• The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices

  2020cites this paper
• Pineal Gland Tumor Microenvironment.

  2020cites this paper
• Use of DNA Methylation Profiling in Translational Oncology.

  2020cites this paper
• „Chemical exchange saturation transfer“ (CEST)

  2020cites this paper
• The Effects of O6-methyl Guanine DNA-methyl Transferase Promotor Methylation and CpG1, CpG2, CpG3 and CpG4 Methylation on Treatment Response and their Prognostic Significance in Patients with Glioblastoma

  2020cites this paper
• FGF5 methylation is a sensitivity marker of esophageal squamous cell carcinoma to definitive chemoradiotherapy

  2019cites this paper
• 5‑Azacytidine treatment results in nuclear exclusion of DNA methyltransferase‑1, as well as reduced proliferation and invasion in human cytomegalovirus‑infected glioblastoma cells.

  2019cites this paper
• Molecular and immunological rationale for the use of tyrosine kinase inhibitors and immune checkpoint inhibitors in glioblastomas

  2019cites this paper
• Cytoplasmic cyclin D1 regulates glioblastoma dissemination

  2019cites this paper
• Methylation of O6-methylguanine DNA methyltransferase promoter is a predictive biomarker in Chinese melanoma patients treated with alkylating agents

  2018cites this paper
• Exceptional Response to Dacarbazine in Uterine Leiomyosarcoma With Homozygous BRCA2 Deletion Highlights the Role of Homologous Recombination in Response to DNA Damage From Alkylating Agents.

  2018cites this paper
• Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation

  2018cites this paper
• Defining Driver DNA Methylation Changes in Human Cancer

  2018cites this paper
• Regulation of glioblastoma cell proliferation in dependence of cell density and growth factors in vitro

  2018cites this paper
• Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics

  2018cites this paper
• Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)

  2018cites this paper
• Differential Characterization of Temozolomide-Resistant Human Glioma Cells

  2018cites this paper
• Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O6-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma.

  2018cites this paper
• Effects of valproic acid on the susceptibility of human glioma stem cells for TMZ and ACNU

  2018cites this paper
• Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI

  2018cites this paper
• Mifepristone Overcomes Tumor Resistance to Temozolomide Associated with DNA Damage Repair and Apoptosis in an Orthotopic Model of Glioblastoma

  2018cites this paper
• Cancer Stem-Like Cells in Glioblastoma

  2017cites this paper
• Olea europaea Leaf Extract Improves the Efficacy of Temozolomide Therapy by Inducing MGMT Methylation and Reducing P53 Expression in Glioblastoma

  2017cites this paper
• Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives

  2017cites this paper
• Cancer and the omics revolution.

  2017cites this paper
• GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer

  2017cites this paper
• Cancer Stem Cells in Glioblastoma CanCer stem Cell identifiCation

  2017cites this paper
• WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy

  2016cites this paper
• Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma

  2016cites this paper
• Epigenetic alternations and cancer chemotherapy response

  2016cites this paper
• The role of epigenetics in genetic and environmental epidemiology.

  2016cites this paper
• Heterogeneity of MGMT gene promoter methylation and protein expression in serial specimens in newly diagnosed glioblastoma

  2016cites this paper
• The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells

  2016cites this paper
• Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.

  2015cites this paper
• Predictive value of CHFR and MLH1 methylation in human gastric cancer

  2015cites this paper
• CHFR methylation strongly correlates with methylation of DNA damage repair and apoptotic pathway genes in non-small cell lung cancer.

  2015cites this paper
• Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.

  2015cites this paper
• The potential for epigenetic analysis of paediatric CNS tumours to improve diagnosis, treatment and prognosis.

  2015cites this paper
• Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.

  2015cites this paper
• Detection of MGMT promoter methylation in glioblastoma using pyrosequencing

  2015cites this paper
• MGMT promoter methylation is associated with temozolomide response and prolonged progression‐free survival in disseminated cutaneous melanoma

  2015cites this paper
• MGMT Promoter Methylation and Glioblastoma: A Comparison of Analytical Methods and of Tumor Specimens

  2015cites this paper
• Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review)

  2015cites this paper
• Concurrence of Multiple Sclerosis and Brain Tumors

  2015cites this paper
• Defining the molecular profile of oral tongue squamous cell carcinomas and its impact on patient outcome

  2014cites this paper
• WITHAFERIN A: A NOVEL THERAPEUTIC APPROACH FOR MALIGANT BRAIN TUMORS

  2014influential citation
• Silencing of hypoxia-inducible tumor suppressor lysyl oxidase gene by promoter methylation activates carbonic anhydrase IX in nasopharyngeal carcinoma.

  2014cites this paper
• Characterization of the DNA methylation patterns of chemosensitive and chemoresistant human cancer cells: Biological and clinical impact

  2014cites this paper
• Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation

  2014cites this paper
• DNA Methylation Biomarkers: Cancer and Beyond

  2014influential citation
• Effect of DNA repair deficiencies on the cytotoxicity of drugs used in cancer therapy - a review.

  2014cites this paper
• Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.

  2014cites this paper
• Epigenetic primer for diagnostic applications: a window into personalized medicine.

  2014cites this paper
• Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy.

  2014cites this paper
• Combination Treatment with Theranostic Nanoparticles for Glioblastoma Sensitization to TMZ

  2014cites this paper
• The good, the bad and the ugly: Epigenetic mechanisms in glioblastoma

  2013cites this paper
• cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome

  2013cites this paper
• DNA Damage, DNA Repair and Cancer

  2013cites this paper
• Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers

  2013cites this paper
• Restoration of Sensitivity in Chemo — Resistant Glioma Cells by Cold Atmospheric Plasma

  2013cites this paper
• Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer

  2013cites this paper
• Effect of lomeguatrib–temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells

  2013cites this paper
• Cell survival and radiosensitisation: modulation of the linear and quadratic parameters of the LQ model (Review).

  2013cites this paper
• Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status

  2013cites this paper
• MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-analysis.

  2013cites this paper
• Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.

  2013cites this paper
• DNA methylation based biomarkers: practical considerations and applications.

  2012cites this paper
• Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab.

  2012cites this paper
• Beyond Pharmacogenetics

  2012cites this paper
• Treatment of elderly patients with glioblastoma: from clinical evidence to molecular highlights.

  2012cites this paper
• Biomarkers to assess the targeting of DNA repair pathways to augment tumor response to therapy.

  2012cites this paper
• Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells

  2012cites this paper
• Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations.

  2012cites this paper
• A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine.

  2012cites this paper
• Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma

  2012cites this paper
• O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems.

  2012cites this paper
• MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

  2012cites this paper
• Genetics of adult glioma.

  2012cites this paper
• MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

  2012cites this paper
• Cancer Pharmacogenomics

  2012cites this paper
• IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma

  2012cites this paper
• O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry.

  2011cites this paper